3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Wilms Tumor
2
Sarcoma, Ewing
2
Sarcoma
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Osteosarcoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neuroblastoma
2
Medulloblastoma
2
Lymphoma, Non-Hodgkin
2
Histiocytosis, Langerhans-Cell
2
Hepatoblastoma
2
Glioma
2
Ependymoma
2
Xanthogranuloma, Juvenile
1
Thyroid Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Pheochromocytoma
1
Melanoma
1
Histiocytic Sarcoma
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Central Nervous System Neoplasms
1
Interventions
Whole-Body Irradiation
5
fludarabine phosphate
4
Cyclophosphamide
4
Peripheral Blood Stem Cell Transplantation
3
Mycophenolic Acid
3
Cyclosporine
3
Busulfan
3
Tacrolimus
2
Methotrexate
2
Melphalan
2
Etoposide
2
Azacitidine
2
venetoclax
1
merphos
1
ivosidenib
1
fludarabine
1
Vorinostat
1
Thiotepa
1
TAK-243
1
Specimen Handling
1
Sirolimus
1
Rituximab
1
Lenalidomide
1
Cord Blood Stem Cell Transplantation
1
Clofarabine
1
CT-P10
1
Biopsy
1
Antilymphocyte Serum
1
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Anemia, Refractory, with Excess of Blasts
×
tipifarnib
×
30 days
×
Clear all
No trials found.